Abdul Naveed Shaik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Abdul Naveed Shaik has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Barbara W. LeDuc
Department of Pharmaceutical Sciences, MCPHS University, Boston, MA, 02115, USA
3 shared publications- Amanda C. Kentner
School of Arts & Sciences, Health Psychology Program, Massachusetts College of Pharmacy and Health Sciences, Boston, USA
2 shared publications David A. Williams
Department of Pharmaceutical Sciences, MCPHS University, 179 Longwood Avenue, Boston, Massachusetts 02115
2 shared publicationsE.J. Connors
School of Arts & Sciences, Health Psychology Program, MCPHS University (formerly Massachusetts College of Pharmacy & Health Sciences), Boston, MA 02115, United States
2 shared publicationsLawrence L. Gan
Development Center for Biotechnology, Taipei 221, Taiwan
2 shared publicationsM.M. Migliore
School of Pharmacy, MCPHS University, Boston, MA 02115, United States
2 shared publications
Latest Publications
- Open Access
- 28 June 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (5) , 1231-1239
Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
There is an unmet need for safe and efficacious oral therapies for COVID‐19 with low potential for drug–drug interactions. Obeldesivir is an orally administered nucleoside prodrug that has shown antiviral potency in nonclinical studies against SARS‐CoV‐2 and its circulating variants. Obeldesivir is metabolized to the active nucleoside triphosphate (GS‐443902), which acts as an inhibitor of the SARS‐CoV‐2 RNA‐dependent RNA polymerase, thereby inhibiting viral RNA synthesis. Here, we report the safety, tolerability, and pharmacokinetics from a first‐in‐human, randomized, placebo‐controlled, phase I study following oral administration of obeldesivir and a phase I, open‐label absorption, distribution, metabolism, and excretion study following oral administration of [14C]‐obeldesivir. Overall, obeldesivir was safe and well tolerated at single and multiple doses between 100 and 1,600 mg, with low potential for QT prolongation as assessed by QT‐concentration analysis. The exposures to GS‐441524 increased dose proportionally in the 100–900‐mg dose range. GS‐441524 accumulated by 35% after twice‐daily and 12% after once‐daily dosing for 5 days. Dose‐proportional increases in the intracellular concentration of GS‐443902 were also observed in peripheral blood mononuclar cells. Plasma exposure of GS‐441524 was not significantly altered by food intake. Following oral administration of [14C]‐obeldesivir (500 mg; 100 μCi), the mean cumulative [14C]‐dose recovery was 90.7% with 58.5% in urine and 32.2% in feces. GS‐441524 was the predominant plasma component (90% of 14C‐area under the concentration–time curve) and was primarily eliminated via renal excretion. Collectively, data from these studies support selection of the obeldesivir 350 mg twice‐daily dosing regimen for further evaluation in phase III studies for COVID‐19.
- 28 June 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (5) , 1231-1239
Open AccessPharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
There is an unmet need for safe and efficacious oral therapies for COVID‐19 with low potential for drug–drug interactions. Obeldesivir is an orally administered nucleoside prodrug that has shown antiviral potency in nonclinical studies against SARS‐CoV‐2 and its circulating variants. Obeldesivir is metabolized to the active nucleoside triphosphate (GS‐443902), which acts as an inhibitor of the SARS‐CoV‐2 RNA‐dependent RNA polymerase, thereby inhibiting viral RNA synthesis. Here, we report the safety, tolerability, and pharmacokinetics from a first‐in‐human, randomized, placebo‐controlled, phase I study following oral administration of obeldesivir and a phase I, open‐label absorption, distribution, metabolism, and excretion study following oral administration of [14C]‐obeldesivir. Overall, obeldesivir was safe and well tolerated at single and multiple doses between 100 and 1,600 mg, with low potential for QT prolongation as assessed by QT‐concentration analysis. The exposures to GS‐441524 increased dose proportionally in the 100–900‐mg dose range. GS‐441524 accumulated by 35% after twice‐daily and 12% after once‐daily dosing for 5 days. Dose‐proportional increases in the intracellular concentration of GS‐443902 were also observed in peripheral blood mononuclar cells. Plasma exposure of GS‐441524 was not significantly altered by food intake. Following oral administration of [14C]‐obeldesivir (500 mg; 100 μCi), the mean cumulative [14C]‐dose recovery was 90.7% with 58.5% in urine and 32.2% in feces. GS‐441524 was the predominant plasma component (90% of 14C‐area under the concentration–time curve) and was primarily eliminated via renal excretion. Collectively, data from these studies support selection of the obeldesivir 350 mg twice‐daily dosing regimen for further evaluation in phase III studies for COVID‐19.
- Open Access
- 23 February 2019
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 7 (1) , 1-3
Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
Physiologically based pharmacokinetic (PBPK) modeling is a mechanistic or physiology based mathematical modeling technique which integrates the knowledge from both drug-based properties including physiochemical and biopharmaceutical properties and system based or physiological properties to generate a model for predicting the absorption, distribution, metabolism and excretion (ADME) properties of a drug as well as pharmacokinetic behavior of a drug in preclinical species and humans.
- 23 February 2019
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 7 (1) , 1-3
Open AccessPhysiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
Physiologically based pharmacokinetic (PBPK) modeling is a mechanistic or physiology based mathematical modeling technique which integrates the knowledge from both drug-based properties including physiochemical and biopharmaceutical properties and system based or physiological properties to generate a model for predicting the absorption, distribution, metabolism and excretion (ADME) properties of a drug as well as pharmacokinetic behavior of a drug in preclinical species and humans.
- Open Access
- 22 June 2017
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 5 (2) , 57-58
Role of drug transporters in drug development: a qualitative and quantitative approach
Editorial for special issue of the journal
- 22 June 2017
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 5 (2) , 57-58
Open AccessRole of drug transporters in drug development: a qualitative and quantitative approach
Editorial for special issue of the journal
- 9 February 2017
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 42 (5) , 827-834
Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation
1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics. In the present investigation, 1-Aminobenzotriazole and ketoconazole are characterized as potent monoamine oxidase (MAO) inhibitors in vitro using mouse, rat and human liver microsomes and S9 fractions.
- 9 February 2017
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 42 (5) , 827-834
Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation
1-Aminobenzotriazole, a known time-dependent inhibitor of cytochrome P450 (CYP) enzymes, and ketoconazole, a strong inhibitor of the human CYP3A4 isozyme, are used as standard probe inhibitors to characterize the CYP and/or non-CYP-mediated metabolism of xenobiotics. In the present investigation, 1-Aminobenzotriazole and ketoconazole are characterized as potent monoamine oxidase (MAO) inhibitors in vitro using mouse, rat and human liver microsomes and S9 fractions.
- Open Access
- 29 June 2016
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 4 (2) , 60-61
Changing trends in use of hepatocytes and microsomes for evaluating metabolism studies in drug discovery
Changing trends in use of hepatocytes and microsomes for evaluating metabolism studies in drug discovery
- 29 June 2016
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 4 (2) , 60-61
Open AccessChanging trends in use of hepatocytes and microsomes for evaluating metabolism studies in drug discovery
Changing trends in use of hepatocytes and microsomes for evaluating metabolism studies in drug discovery
- Open Access
- 29 June 2016
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 4 (2) , 114-116
Is there a paradigm shift in use of microsomes and hepatocytes in drug discovery and development?
Is there a paradigm shift in use of microsomes and hepatocytes in drug discovery and development?
- 29 June 2016
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 4 (2) , 114-116
Open AccessIs there a paradigm shift in use of microsomes and hepatocytes in drug discovery and development?
Is there a paradigm shift in use of microsomes and hepatocytes in drug discovery and development?
- Open Access
- 29 June 2016
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 4 (2) , 84-90
Metabolism of six CYP probe substrates in fetal hepatocytes
Cytochrome P-450 (CYP) are the most common drug metabolizing enzymes and are abundantly expressed in liver apart from kidney, lungs, intestine, brain etc. Their expression levels change with physiological conditions and disease states. The expression of these CYPs is less in human foetus and neonates compared to adults, which results in lower clearance of xenobiotics in infants and neonates compared to adults. Hepatocytes are the cells which are largely used to study these CYPs. We have isolated hepatocytes from aborted foetus to study the metabolism of six probe substrates: phenacetin, diclofenac, S-mephenytoin, dextromethorphan, nifedipine and testosterone. The results obtained show the expression of various CYPs (CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4) in human foetus and their involvement in metabolism of CYP probe substrates.
- 29 June 2016
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 4 (2) , 84-90
Open AccessMetabolism of six CYP probe substrates in fetal hepatocytes
Cytochrome P-450 (CYP) are the most common drug metabolizing enzymes and are abundantly expressed in liver apart from kidney, lungs, intestine, brain etc. Their expression levels change with physiological conditions and disease states. The expression of these CYPs is less in human foetus and neonates compared to adults, which results in lower clearance of xenobiotics in infants and neonates compared to adults. Hepatocytes are the cells which are largely used to study these CYPs. We have isolated hepatocytes from aborted foetus to study the metabolism of six probe substrates: phenacetin, diclofenac, S-mephenytoin, dextromethorphan, nifedipine and testosterone. The results obtained show the expression of various CYPs (CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4) in human foetus and their involvement in metabolism of CYP probe substrates.
- 19 April 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 105 (6) , 1976-1986
Mechanism of Drug-Drug Interactions Between Warfarin and Statins
- 19 April 2016
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 105 (6) , 1976-1986
Mechanism of Drug-Drug Interactions Between Warfarin and Statins
- 1 January 2016
- Published by Elsevier in Journal of Chromatography B
- Vol. 1008, 164-173
Comparison of enzyme kinetics of warfarin analyzed by LC–MS/MS QTrap and differential mobility spectrometry
- 1 January 2016
- Published by Elsevier in Journal of Chromatography B
- Vol. 1008, 164-173
Comparison of enzyme kinetics of warfarin analyzed by LC–MS/MS QTrap and differential mobility spectrometry
- 1 February 2015
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 52, 153-167
Environmental enrichment models a naturalistic form of maternal separation and shapes the anxiety response patterns of offspring
- 1 February 2015
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 52, 153-167
Environmental enrichment models a naturalistic form of maternal separation and shapes the anxiety response patterns of offspring